Tag:
Spectrum Pharmaceuticals
Latest Headlines
Latest Headlines
Spectrum nabs Allos buyout as bladder cancer drug fails PhIII
Spectrum Pharmaceuticals ($SPPI) put on the best face possible on the news that its bladder cancer drug apaziquone failed two late stage studies.
FDA works to avert cancer drug shortage
A recent example of the FDA stepping in to help alleviate a drug shortage involves high-flying Spectrum Pharmaceuticals and its anticancer drug, Fusilev (levoleucovorin, in 50-mg single-use vials).
Shulman: Best biotech stocks to own
This morning, MarketWatch's Michael Shulman listed some of what he sees are the hottest bargain biotech stocks for this year: Cerus, Curis, Compugen, Spectrum Pharmaceuticals and Impax Laboratories.
Spectrum partners up on new program for rituximab biosimilar
Spectrum Pharmaceuticals ( $SPPI ) is jumping into the biosimilar business. In a brief announcement this morning, the Irvine, CA-based biotech said that it has inked a deal with Viropro to develop a
Spectrum sues Cangene for breach of contract
Irvine, California-based Spectrum Pharmaceuticals is suing Cangene Biopharma in the U.S. District Court in Baltimore for allegedly breaching a 2008 contract to make Fusilev, an injectable cancer
Spectrum adds to cancer pipeline with $350M deal
Spectrum Pharmaceuticals is paying $30 million down and up to $320 million in cash and a million shares of stock for a significant share of the worldwide rights to a late-stage cancer compound
Spectrum Pharma dumps disappointing BPH therapy
Dogged by disappointing data and daunted by the commercial prospects of their experimental drug for enlarged prostate, Spectrum Pharmaceuticals announced this morning that it is shelving its program
FDA rejects new indication for Spectrum drug
The FDA declined to approve a supplementary marketing application for Spectrum Pharmaceuticals' cancer drug Fusilev. Currently approved for bone cancer, the company was hoping it could expand the
FDA accepts Spectrum's Zevalin response
The FDA has accepted for review Spectrum Pharmaceuticals' response on the experimental cancer drug Zevalin as a Class 1 submission, setting a deadline of September 7 for its final decision. That's
FDA asks for more Zevalin info
The FDA is seeking more information on Spectrum Pharmaceuticals' cancer drug Zevalin. And that news cut into the company's share price, which dropped 15 percent. Spectrum swiftly countered by
